WO2011108882A3 - 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 - Google Patents

유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2011108882A3
WO2011108882A3 PCT/KR2011/001497 KR2011001497W WO2011108882A3 WO 2011108882 A3 WO2011108882 A3 WO 2011108882A3 KR 2011001497 W KR2011001497 W KR 2011001497W WO 2011108882 A3 WO2011108882 A3 WO 2011108882A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
prevention
treatment
active ingredient
containing rebamipide
Prior art date
Application number
PCT/KR2011/001497
Other languages
English (en)
French (fr)
Other versions
WO2011108882A2 (ko
Inventor
민준기
조미라
우윤주
오혜좌
정영옥
이근혁
최병선
박진하
곽은영
Original Assignee
가톨릭대학교 산학협력단
한림제약 (주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단, 한림제약 (주) filed Critical 가톨릭대학교 산학협력단
Priority to CA2791526A priority Critical patent/CA2791526A1/en
Priority to JP2012556024A priority patent/JP5769319B2/ja
Priority to EP11750939.8A priority patent/EP2543374B1/en
Priority to US13/582,929 priority patent/US9301954B2/en
Priority to ES11750939.8T priority patent/ES2501047T3/es
Priority to BR112012020415A priority patent/BR112012020415A2/pt
Priority to CN2011800124634A priority patent/CN102791272A/zh
Priority to RU2012136190/15A priority patent/RU2545768C2/ru
Publication of WO2011108882A2 publication Critical patent/WO2011108882A2/ko
Publication of WO2011108882A3 publication Critical patent/WO2011108882A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 레바미피드 및 약학적으로 허용가능한 담체를 포함하는 골관절염의 예방 또는 치료용 약학 조성물을 제공한다. 상기 약학 조성물은 경구 투여용 형태일 수 있으며, 바람직하게는 정제 또는 캅셀제 형태의 고형 경구용 제형을 가질 수 있다. 또한, 상기 약학 조성물은 레바미피드가 0.5 내지 50 mg/kg, 더욱 바람직하게는 0.6 내지 6 mg/kg의 용량으로 경구투여되기에 적합한 단위 투여 형태(unit dosage form)로 제제화될 수 있다.
PCT/KR2011/001497 2010-03-05 2011-03-04 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 WO2011108882A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2791526A CA2791526A1 (en) 2010-03-05 2011-03-04 Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
JP2012556024A JP5769319B2 (ja) 2010-03-05 2011-03-04 活性成分としてレバミピドを含む骨関節炎の予防用または治療用の薬学組成物
EP11750939.8A EP2543374B1 (en) 2010-03-05 2011-03-04 Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
US13/582,929 US9301954B2 (en) 2010-03-05 2011-03-04 Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
ES11750939.8T ES2501047T3 (es) 2010-03-05 2011-03-04 Composición farmacéutica para la prevención o tratamiento de la osteoartritis, que contiene rebamipida como principio activo
BR112012020415A BR112012020415A2 (pt) 2010-03-05 2011-03-04 composição farmacêutica para a prevenção ou tratamento da osteoartrite
CN2011800124634A CN102791272A (zh) 2010-03-05 2011-03-04 含有瑞巴派特作为有效成分的用于预防或治疗骨关节炎的药学组合物
RU2012136190/15A RU2545768C2 (ru) 2010-03-05 2011-03-04 Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0019671 2010-03-05
KR1020100019671A KR101182114B1 (ko) 2010-03-05 2010-03-05 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
WO2011108882A2 WO2011108882A2 (ko) 2011-09-09
WO2011108882A3 true WO2011108882A3 (ko) 2012-01-12

Family

ID=44542738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001497 WO2011108882A2 (ko) 2010-03-05 2011-03-04 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물

Country Status (10)

Country Link
US (1) US9301954B2 (ko)
EP (1) EP2543374B1 (ko)
JP (1) JP5769319B2 (ko)
KR (1) KR101182114B1 (ko)
CN (1) CN102791272A (ko)
BR (1) BR112012020415A2 (ko)
CA (1) CA2791526A1 (ko)
ES (1) ES2501047T3 (ko)
RU (1) RU2545768C2 (ko)
WO (1) WO2011108882A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395984B1 (ko) * 2011-10-21 2014-05-16 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
SA113340675B1 (ar) 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
WO2016108319A1 (ko) * 2015-01-02 2016-07-07 삼진제약 주식회사 신규 레바미피드 전구체의 염 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004641A (ko) * 2001-05-25 2004-01-13 오츠카 세이야쿠 가부시키가이샤 의약용 조성물
KR20040073255A (ko) * 2003-02-12 2004-08-19 알앤피코리아주식회사 용출률이 향상된 난용성 약제의 용매 시스템 및 이를함유한 제약학적 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011026A1 (en) * 1993-10-21 1995-04-27 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative for inhibiting production of interleukin-8
WO1998010057A1 (en) * 1996-09-06 1998-03-12 Emory University Methods for testing compounds for use as therapeutic antioxidants
AR015426A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
US8883761B2 (en) * 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
AU2003261633A1 (en) * 2003-02-12 2004-09-06 R And P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
KR101104634B1 (ko) * 2009-08-25 2012-01-12 한림제약(주) 레바미피드를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004641A (ko) * 2001-05-25 2004-01-13 오츠카 세이야쿠 가부시키가이샤 의약용 조성물
KR20040073255A (ko) * 2003-02-12 2004-08-19 알앤피코리아주식회사 용출률이 향상된 난용성 약제의 용매 시스템 및 이를함유한 제약학적 제제

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOHASHI, M. ET AL.: "Effective treatment with oral administration ofrebamipide in a mouse model of sjogren's syndrome", ARTHRITIS & RHEUMATISM, vol. 58, no. 2, 2008, pages 389 - 400, XP008151508, DOI: doi:10.1002/art.23163 *
MIYATA, M. ET AL.: "Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: A case report", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 12, no. 4, 2006, pages 656 - 658, XP009170050, DOI: doi:10.3748/wjg.v12.i4.656 *
See also references of EP2543374A4 *

Also Published As

Publication number Publication date
ES2501047T3 (es) 2014-10-01
EP2543374A4 (en) 2013-07-10
EP2543374A2 (en) 2013-01-09
KR101182114B1 (ko) 2012-09-12
WO2011108882A2 (ko) 2011-09-09
RU2545768C2 (ru) 2015-04-10
JP5769319B2 (ja) 2015-08-26
CN102791272A (zh) 2012-11-21
US20130065920A1 (en) 2013-03-14
BR112012020415A2 (pt) 2016-05-17
EP2543374B1 (en) 2014-07-09
CA2791526A1 (en) 2011-09-09
US9301954B2 (en) 2016-04-05
JP2013521277A (ja) 2013-06-10
RU2012136190A (ru) 2014-04-10
KR20110100700A (ko) 2011-09-15

Similar Documents

Publication Publication Date Title
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
WO2012079092A3 (en) Testosterone undecanoate compositions
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
JP2011068653A5 (ko)
JP2013511507A5 (ko)
WO2012054831A3 (en) Ready to use ketorolac formulations
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
JP2013509395A5 (ko)
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
MY160732A (en) A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
WO2010098627A3 (ko) 약제학적 제제
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
JP2016514706A5 (ko)
EP1949900A3 (en) Controlled release solid formulation for oral administration as single dose sachet and method of preparation thereof
NZ596881A (en) Phentermine liquid dosage form
IL292725A (en) Benzazepines are combined for the treatment of Tourette syndrome
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180012463.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2011750939

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2791526

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012556024

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13582929

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012136190

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012020415

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012020415

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120815